EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Anti-CTGF/PD-1 bispecific antibody Y126S restrains desmoplastic and immunosuppressive microenvironment in pancreatic cancer

Shiru Chen, Yuchong Zhao, Mengdie Cao, Wang Peng, Hai Huang, Yilei Yang, Jingwen Liang, Wei Chen, Shuya Bai, Qiaodan Zhou, Jiamei Jiang, Yilin Gu und 2 weitere

Journal for ImmunoTherapy of Cancer · 2025-06 · 13 (6) · e012144

DOI: 10.1136/jitc-2025-012144 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 13.06.2025. Verfasst von Shiru Chen und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, …. Hauptthemen laut MEDLINE: Tumor Microenvironment, Pancreatic Neoplasms, Antibodies, Bispecific, Programmed Cell Death 1 Receptor. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Tongji Hospital, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pancreatic ductal adenocarcinoma (PDAC) is characterized by a desmoplastic and immunosuppressive tumor microenvironment (TME), limiting the efficacy of immune checkpoint inhibitors such as anti-programmed cell death 1 (PD-1).

Methods

This study aimed to evaluate the therapeutic potential of Y126S, a recombinant IgG1/IgG2 hybrid bispecific antibody (BsAb), in reshaping the immunotherapy-resistant TME in PDAC. Orthotopic PDAC and KPC (Kras LSL-G12D/+ ; Trp53 LSL-R172H/+ ; Pdx1-Cre) mouse models were established and treated with Y126S, α-connective tissue growth factor (CTGF), α-PD-1, or a combination of α-CTGF and α-PD-1. TME remodeling, antibody distribution, and therapeutic efficacy were assessed using flow cytometry, immunohistochemical/Masson staining, atomic force microscopy, positron emission tomography (PET) imaging, distribution analysis, and other experimental techniques.

Results

Here, Y126S was characterized in vitro and its antitumor efficacy was evaluated and validated in orthotopic PDAC mice and KPC mouse models. Notably, Y126S significantly remodeled the TME and demonstrated superior tumor-specific accumulation compared with single α-PD-1 treatment, leading to markedly enhanced antitumor efficacy relative to its parental antibodies or their combination. Mechanistically, Y126S suppressed cancer-associated fibroblasts (CAFs) activation, reduced collagen deposition, and downregulated programmed cell death ligand 1 (PD-L1) expression on CAFs by targeting CTGF and enhanced the anti-PD-1-mediated reinvigoration of cytotoxic CD8 + T cells, thereby establishing a less desmoplastic and potent tumor-killing microenvironment.

Conclusions

Our findings highlight the potential of Y126S as a promising BsAb-based immunotherapy strategy for PDAC by remodeling the desmoplastic and immunosuppressive TME.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tumor MicroenvironmentPancreatic NeoplasmsAntibodies, BispecificProgrammed Cell Death 1 ReceptorCarcinoma, Pancreatic DuctalAnimalsMiceHumansCell Line, TumorFemale

Stichwörter der Autor:innen

Gastrointestinal CancerImmunotherapyTumor microenvironment - TME

Substanzen

Antibodies, BispecificProgrammed Cell Death 1 Receptor

Autor:innen und Institutionen

  • Department of Gastroenterology and Hepatology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
  • Department of Gastroenterology and Hepatology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China zhaoyuchongtj@163.com b.cheng@tjh.tjmu.edu.cn.
  • Department of Geriatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
  • Key Laboratory of Vascular Aging, Tongji Hospital,Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
  • School of Life Sciences, The Chinese University of Hong Kong, Hong Kong, China.
  • Department of Internal Medicine, University of Pittsburgh Medical Center Mercy Hospital, Pittsburgh, Pennsylvania, USA.

Förderung

  • Tongji Hospital
  • National Natural Science Foundation of China

Zitieren

APA

Chen, S., Zhao, Y., Cao, M., Peng, W., Huang, H., Yang, Y., Liang, J., Chen, W., Bai, S., Zhou, Q., Jiang, J., Gu, Y., Wang, R., & Cheng, B. (2025). Anti-CTGF/PD-1 bispecific antibody Y126S restrains desmoplastic and immunosuppressive microenvironment in pancreatic cancer. Journal for ImmunoTherapy of Cancer, 13(6), e012144. https://doi.org/10.1136/jitc-2025-012144

Vancouver

Chen S, Zhao Y, Cao M, Peng W, Huang H, Yang Y, et al. Anti-CTGF/PD-1 bispecific antibody Y126S restrains desmoplastic and immunosuppressive microenvironment in pancreatic cancer. Journal for ImmunoTherapy of Cancer. 2025;13(6):e012144. doi:10.1136/jitc-2025-012144

BibTeX
@article{Chen2025,
  author = {Chen, Shiru and Zhao, Yuchong and Cao, Mengdie and Peng, Wang and Huang, Hai and Yang, Yilei and Liang, Jingwen and Chen, Wei and Bai, Shuya and Zhou, Qiaodan and Jiang, Jiamei and Gu, Yilin and Wang, Ronghua and Cheng, Bin},
  title = {Anti-CTGF/PD-1 bispecific antibody Y126S restrains desmoplastic and immunosuppressive microenvironment in pancreatic cancer},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2025},
  volume = {13},
  number = {6},
  pages = {e012144},
  doi = {10.1136/jitc-2025-012144}
}
Kostenlos starten →